The National Institutes of Health has been funding fewer clinical trials in recent years, according to new Johns Hopkins University research.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for cancer, respiratory and other diseases, announced today the pricing of its previously announced underwritten public offering of 5,500,000 shares of its common stock at a public offering price of $8.00 per share. The gross proceeds from the offering, before deducting the underwriting discounts and commissions and other estimated offering expenses payable by Pieris, are expected to be $44.0 million. In addition, Pieris has granted the underwriters a 30-day option to purchase up to 825,000 additional shares of common stock at the public offering price, less the underwriting discounts and commissions. The offering is expected to close on or about February 16, 2018, subject to customary closing conditions.
Host: UM BioPark & Wexford Science + Technology
Location: UM BioPark The Nook Cafe 801 W. Baltimore Street Baltimore Maryland 21201
Time: Thursday, February 22, 2018 5:00pm to 6:30pm
Mingle with BioPark tenants, our UM Ventures staff, UMB faculty and leaders in Baltimore’s technology community.
MaxCyte, the global cell-based medicines and technology company, announces that 30-year life sciences industry veteran Richard Douglas, Ph.D., has been appointed to the Company’s Board of Directors as an Independent Non-Executive Director.
Is wood the next advanced material?
Scientists at the University of Maryland reported last week that they’ve discovered a way to treat wood to make it 12 times stronger than natural wood and 10 times tougher. According to Liangbing Hu, one the lead researchers in the paper published in Nature, their wood is so strong and durable that it can compete with steel, titanium alloys, and even carbon fiber–but at an infinitely much lower price point.
Brown Advisory—an investment and strategic advisory firm committed to making a material and positive difference in the lives of its clients—is excited to join forces with network-driven venture capital firm, NextGen Venture Partners (“NextGen”). On Feb. 22, 2018, the NextGen team will officially join their new Brown Advisory colleagues in offices across the United States.
SillaJen, Inc., (KOSDAQ:215600), a clinical-stage, biotherapeutics company focused on the development of oncolytic immunotherapy products for cancer, and ABL Europe, an ABL, Inc. company providing dedicated viral vector GMP services for gene therapy, oncolytic products and vaccines for all stages of clinical supply, have expanded their strategic manufacturing collaboration. Under the current agreement, ABL is currently manufacturing Pexa-Vec (formerly JX-594) for SillaJen’s multinational, randomized Phase 3, open-label study of Pexa-Vec in patients with advanced liver cancer. Under the expanded agreement, ABL will also provide development, manufacturing & QC release testing services for SillaJen’s pipeline product, JX-970.
The ability for cancer cells to develop resistance to chemotherapy drugs – known as multidrug resistance – remains a leading cause for tumor recurrence and cancer metastasis, but recent findings offer hope that oncologists could one day direct cancer cells to “turn off” their resistance capabilities.
In the last six months, Personal Genome Diagnostics (PGDx) raised a $75 million series B, Harpoon Medical sold for $100 million and Sunayu acquired Fractal Technology. Which Baltimore startup is next?
Lonza Pharma & Biotech and Denali Therapeutics (NASDAQ: DNLI) announced today an exclusive strategic partnership on Denali’s biologic pipeline products for neurodegenerative diseases. The agreement covers all stages of the development and manufacturing,